You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 9, 2025

CLINICAL TRIALS PROFILE FOR LATISSE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for LATISSE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT01448525 ↗ Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence Completed Allergan Phase 4 2011-10-01 The purpose of this study is to determine patient satisfaction with LATISSE® treatment for increasing eyelash prominence.
NCT01387906 ↗ Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo Completed Allergan Phase 4 2011-03-01 The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
NCT01387906 ↗ Latisse (Bimatoprost .03% Opthalmic Solution) for the Treatment of Hypotrichosis of the Eyebrows: Latisse Versus Placebo Completed Kenneth Beer Phase 4 2011-03-01 The primary purpose of this study is to assess efficacy and safety of Latisse (bimatoprost .03% ophthalmic solution) applied to the lateral and medial eyebrows. The primary outcome is a increase in overall eyebrow prominence as measured by at least a 1-grade increase on the Global Eyebrow Assessment (GEyA) scale, from baseline to the end of the treatment which will be day 270 period.
NCT01623479 ↗ An Observational Study of Patients Treated With Bimatoprost 0.03% (Latisse®) for Hypotrichosis of the Eyelashes Completed Allergan 2010-11-19 This is an observational study of patients treated with bimatoprost 0.03% (Latisse®) for at least 12 months for hypotrichosis of the eyelashes.
NCT01229423 ↗ Safety and Efficacy of LATISSE® in the Augmentation of Eyelashes of Korean Subjects Completed Allergan Phase 4 2009-11-01 This study will evaluate the safety and efficacy of LATISSE® (bimatoprost 0.03%) in the augmentation of eyelashes in Korean women.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 5 of 5 entries

Clinical Trial Conditions for LATISSE

Condition Name

22110-0.200.20.40.60.811.21.41.61.822.2Eyelash HypotrichosisHypotrichosisDermatochalasisFacial Rhytides[disabled in preview]
Condition Name for LATISSE
Intervention Trials
Eyelash Hypotrichosis 2
Hypotrichosis 2
Dermatochalasis 1
Facial Rhytides 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

51110-0.500.511.522.533.544.555.5HypotrichosisCutis LaxaFaciesAlopecia Areata[disabled in preview]
Condition MeSH for LATISSE
Intervention Trials
Hypotrichosis 5
Cutis Laxa 1
Facies 1
Alopecia Areata 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for LATISSE

Trials by Country

+
Trials by Country for LATISSE
Location Trials
United States 6
Korea, Republic of 1
Sweden 1
Russian Federation 1
United Kingdom 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for LATISSE
Location Trials
California 3
Florida 2
Louisiana 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for LATISSE

Clinical Trial Phase

57.1%14.3%14.3%14.3%011.522.533.54Phase 4Phase 3Phase 2[disabled in preview]
Clinical Trial Phase for LATISSE
Clinical Trial Phase Trials
Phase 4 4
Phase 3 1
Phase 2 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

100.0%0012345678Completed[disabled in preview]
Clinical Trial Status for LATISSE
Clinical Trial Phase Trials
Completed 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for LATISSE

Sponsor Name

trials01234567AllerganKenneth BeerDuke University[disabled in preview]
Sponsor Name for LATISSE
Sponsor Trials
Allergan 7
Kenneth Beer 1
Duke University 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

70.0%30.0%001234567IndustryOther[disabled in preview]
Sponsor Type for LATISSE
Sponsor Trials
Industry 7
Other 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

LATISSE Market Analysis and Financial Projection

Latisse (Bimatoprost): Clinical Trials, Market Analysis, and Projections

Introduction

Latisse, a synthetic prostaglandin analog known as bimatoprost, has revolutionized the treatment of hypotrichosis (inadequate or insufficient eyelashes) since its FDA approval in 2008. Here, we delve into the clinical trials that led to its approval, the current market analysis, and future projections for this groundbreaking drug.

Clinical Trials and Efficacy

Primary Clinical Study

The pivotal clinical trial for Latisse involved a multicenter, double-masked, randomized, vehicle-controlled study. This 16-week study included 278 adult patients and evaluated the effect of Latisse on overall eyelash prominence. The primary efficacy endpoint was an increase in overall eyelash prominence as measured by at least a 1-grade increase from baseline to the end of the treatment period[1][3].

Key Findings

  • By the end of the 16-week treatment period, patients treated with Latisse experienced statistically significant improvements in eyelash length, thickness, and darkness compared to the vehicle group.
  • Specifically, lashes were 106% fuller, 25% longer, and 18% darker in the Latisse group compared to minimal changes in the placebo group[4].
  • The study also reported that the most common adverse events were non-serious and cosmetic in nature, including eye redness, itchy eyes, and skin hyperpigmentation[3].

Pediatric and Special Populations

Latisse was also evaluated in pediatric patients, including those post-chemotherapy and those with alopecia areata. These studies showed significant improvements in eyelash growth, although the efficacy and safety profiles varied slightly among different age groups and conditions[1].

Market Analysis

Current Market Size and Growth

As of 2023, the global Latisse (bimatoprost) market has shown substantial growth. The market size in 2023 was valued at millions of dollars, with a projected compound annual growth rate (CAGR) that indicates continued expansion from 2024 to 2031[2][5].

Regional Market Share

North America dominates the Latisse market, holding approximately 90% of the regional share. Other significant regions include Europe, Asia Pacific, and Latin America, each contributing to the global market growth[5].

Competitive Landscape

The market is led by key players such as Cayman Pharma, Tecoland Corporation, TCS Group, and others. These companies are focusing on expanding their product portfolios and strengthening their market presence through strategic initiatives[2][5].

Market Projections

Forecast Period

From 2024 to 2031, the Latisse market is expected to witness significant growth. The forecasted data indicates a steady increase in market size, driven by increasing demand for aesthetic treatments and the expanding reach of the product in various regions[2][5].

Segment Analysis

The market is segmented by type (patented product vs. general products) and application. The patented product segment is expected to expand at a significant CAGR, retaining its position throughout the forecast period. This growth is attributed to the exclusive rights held by Allergan (now part of AbbVie) for the use of bimatoprost and other prostaglandin analogs in stimulating eyelash growth[2][5].

Drivers and Opportunities

Key drivers of the market include the growing demand for aesthetic treatments, the favorable safety profile of Latisse, and the increasing awareness of the product among consumers. Opportunities for growth are further enhanced by the expansion of the product into new markets and the development of new applications for bimatoprost[2].

Safety and Usage

Important Safety Information

Latisse is intended for use on the upper eyelid margins at the base of the eyelashes. It is crucial to avoid applying the solution to the lower eyelid. Patients using LUMIGAN or other products for elevated intraocular pressure (IOP) should use Latisse under close medical supervision[3].

Long-term Safety

The long-term safety of bimatoprost has been well established through its use in over 32 clinical trials involving more than 5,700 glaucoma patients and over 13 years of clinical trial experience. This extensive safety data supports the favorable safety profile of Latisse[3].

Key Takeaways

  • Clinical Efficacy: Latisse has demonstrated statistically significant improvements in eyelash length, thickness, and darkness in clinical trials.
  • Market Growth: The global Latisse market is projected to grow significantly from 2024 to 2031, driven by increasing demand and expanding market reach.
  • Competitive Landscape: Key players dominate the market, with a focus on expanding product portfolios and market presence.
  • Safety Profile: Latisse has a favorable safety profile, with long-term safety data supporting its use.

FAQs

What is Latisse and how does it work?

Latisse is a synthetic prostaglandin analog (bimatoprost) that stimulates the growth of eyelashes, making them longer, thicker, and darker.

What were the key findings of the clinical trials for Latisse?

Clinical trials showed that Latisse significantly increased eyelash length, thickness, and darkness compared to the placebo group, with minimal adverse effects.

Which regions dominate the Latisse market?

North America holds the largest share of the Latisse market, followed by Europe, Asia Pacific, and Latin America.

Who are the key players in the Latisse market?

Key players include Cayman Pharma, Tecoland Corporation, TCS Group, and others.

What is the projected growth rate of the Latisse market from 2024 to 2031?

The market is expected to grow at a significant CAGR from 2024 to 2031, driven by increasing demand and market expansion.

What are the common adverse effects of using Latisse?

Common adverse effects include eye redness, itchy eyes, and skin hyperpigmentation, which are generally non-serious and cosmetic in nature.

Sources

  1. LATISSE (bimatoprost) Label - accessdata.fda.gov
  2. Latisse Bimatoprost Market Report 2024 - cognitivemarketresearch.com
  3. Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse - fiercebiotech.com
  4. RESULTS | LATISSE® - latisse.com
  5. Global Latisse (Bimatoprost) Market Research Report 2024 - valuates.com

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.